Back to Search
Start Over
Development of Furanopyrimidine-Based Orally Active Third-Generation EGFR Inhibitors for the Treatment of Non-Small Cell Lung Cancer
- Source :
- Journal of Medicinal Chemistry. 66:2566-2588
- Publication Year :
- 2023
- Publisher :
- American Chemical Society (ACS), 2023.
- Subjects :
- Drug Discovery
Molecular Medicine
Subjects
Details
- ISSN :
- 15204804 and 00222623
- Volume :
- 66
- Database :
- OpenAIRE
- Journal :
- Journal of Medicinal Chemistry
- Accession number :
- edsair.doi...........22f10aa3b2e138d40b42d98f5b533645
- Full Text :
- https://doi.org/10.1021/acs.jmedchem.2c01434